The Non-Malignant Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | Novel agents being explored for the treatment of immune-mediated TTP
Júlia Weisinger, MD, Hospital Saint-Antoine AP-HP, Paris, France, discusses new treatments for immune-mediated thrombotic thrombocytopenic purpura (TTP). She highlights novel anti-CD20 agents like obinutuzumab and ofatumumab, which show efficacy in patients refractory to rituximab, as well as the potential use of the calcineurin inhibitor cyclosporine in the preemptive setting. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
